Document Detail

Benefits and risks of live attenuated influenza vaccine in young children.
MedLine Citation:
PMID:  20873950     Owner:  NLM     Status:  In-Data-Review    
OBJECTIVE: To examine the benefit-risk profile of live attenuated influenza vaccine (LAIV) across a range of clinical scenarios in which we varied assumptions regarding both the percentage of children who would receive LAIV in lieu of trivalent inactivated influenza virus (TIV) and the extent of off-label use. STUDY DESIGN: Model of expected benefits and risks of immunization of young children against influenza. METHODS: We estimated expected numbers of cases of influenza illness (FLU), medically significant wheezing (MSW), and hospitalization in a single influenza season under alternative assumptions regarding use of LAIV in lieu of TIV, based on projections from a large phase III trial. RESULTS: Assuming no use of LAIV in nonindicated children (aged <24 months and those with history of recurrent wheezing or asthma), and 50% use in lieu of TIV among children in the indicated population, there would be 2099 fewer FLU cases per 100,000 children aged 12 to 59 months, and no change in MSW or hospitalization. If LAIV also were used in lieu of TIV among 20% of children aged 12 to 23 months and 20% of children aged 24 to 59 months with a history of recurrent wheezing or asthma, there would be a further reduction of 397 FLU cases and 12 hospitalizations per 100,000 children aged 12 to 59 months, but 51 additional MSW cases. CONCLUSIONS: Our study suggests that even if LAIV were sometimes used inadvertently in clinical practice in young children for whom it is not indicated, the overall balance of expected benefits and risks would remain favorable.
Gerry Oster; Derek Weycker; John Edelsberg; Kristin L Nichol; Jerome O Klein; Robert B Belshe
Publication Detail:
Type:  Journal Article     Date:  2010-09-01
Journal Detail:
Title:  The American journal of managed care     Volume:  16     ISSN:  1936-2692     ISO Abbreviation:  Am J Manag Care     Publication Date:  2010  
Date Detail:
Created Date:  2010-09-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9613960     Medline TA:  Am J Manag Care     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e235-44     Citation Subset:  H    
Policy Analysis, Inc, Four Davis Ct, Brookline, MA 02445. E-mail:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting.
Next Document:  Controlling hypertension requires a new primary care model.